NCT00594308 · OUTCOME

Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.

In-Vivo Activated T-Cell Depletion to Prevent GVHD · Source last updated 2014-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of patients who died due to transplant related toxicities

Analysis population: Intent To Treat: All patients that received study drug

All patients that received Basiliximab 20 mg monoclonal therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Basiliximab 20 mg	10

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Basiliximab 20 mg	10	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of patients who died due to transplant related toxicities

groups

param Type

NUMBER

population Description

Intent To Treat: All patients that received study drug

time Frame

up to 2 years after stem cell transplant

title

Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice